Whitehawk Therapeutics
WHWK
24 hedge funds and large institutions have $6.46M invested in Whitehawk Therapeutics in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.87% less ownership
Funds ownership: 24.28% → 23.41% (-0.87%)
44% less capital inflows, than outflows
Capital inflows: $329K | Capital outflows: $593K
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Johnson Investment Counsel
Cincinnati,
Ohio
|
+$237K |
| 2 |
Renaissance Technologies
New York
|
+$72K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$15.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.43K |
| 5 |
BlackRock
New York
|
+$2.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tekla Capital Management
Boston,
Massachusetts
|
-$356K |
| 2 |
Goldman Sachs
New York
|
-$78.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$76.8K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
-$41.9K |
| 5 |
First Allied Advisory Services
San Diego,
California
|
-$11K |
WHWK Hedge Fund Activity: Q3 2019 in Review
24 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2019, worth a combined $6.46M — down 28% from $8.96M a quarter earlier.
Fund positioning in WHWK was balanced in Q3 2019: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 8 trimmed.
The largest buyer was Johnson Investment Counsel, opening a new position worth an estimated $237K. The largest seller was Tekla Capital Management, cutting an estimated $356K.
- 24 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $6.46M of Whitehawk Therapeutics stock for Q3 2019, down 28% quarter-over-quarter.
- 2 funds opened new Whitehawk Therapeutics positions in Q3 2019 and 2 closed out, a net change of 0 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2019 was Johnson Investment Counsel, an estimated $237K added.
- The largest Whitehawk Therapeutics seller in Q3 2019 was Tekla Capital Management, an estimated $356K sold.
Based on aggregated 13F filings for Q3 2019.